Fibrogen And Galapagos Raise Lung Disease Hopes

Aug. 14, 2017 12:15 PM ETFibroGen, Inc. (FGEN), GLPGBIIB, SNY, RHHBY, BMY, LMNL, GBT2 Comments
EP Vantage profile picture
EP Vantage

Important new data on novel idiopathic pulmonary fibrosis candidates look set to continue to emerge in the wake of two encouraging reports in the past couple of weeks. Biogen (BIIB), Promedior, Sanofi (SNY) and Roche (OTCQX:RHHBY) are all due to unveil fresh information from mid-stage candidates before the end of the year.

These projects will follow updates from Fibrogen (NASDAQ:FGEN) and Galapagos (NASDAQ:GLPG), both of which raised hopes for new mechanisms in this field. To date no drug has managed to completely arrest the inevitable decline in lung function that is the hallmark of this devastating disease, so the bar to success remains very high, but with several shots on goal looming there is some cause for optimism (see table below).

However, any optimism must be tempered with caution, as both the Fibrogen and Galapagos data came from relatively small trials (Pamrevlumab comes off the bench to deliver for Fibrogen, August 8, 2017). And neither can Biogen's silence on BG00011 be an encouraging sign.

Biogen had bought Stromedix for this anti-avb6 integrin antibody, and, while a phase II study ended in March, according to, it has yet to reveal an update; Stromedix fetched $75m up front in 2012, and its private backers will hope to see a bit more of the $488m in milestones heading their way.

Biogen did not respond to an emailed request for an update. Glaxosmithkline has an asset in phase I targeting the same pharmacology, but the industry's idiopathic pulmonary fibrosis (IPF) pipeline is in fact characterised by a remarkable breadth of mechanistic approaches.


Two agents targeting the IL-13 and IL-4 cytokines should yield data towards the end of the year. Sanofi is testing its bispecific antibody in the large Estair study, while Roche has lebrikuzumab in a very expansive phase II trial, which includes Esbriet combination arms.

Presumably Roche's Esbriet and Boehringer Ingelheim's Ofev are considered standard of care now, at least where payers are able to support them, so surely novel molecules will have to be tested in combination with them. However, it is notable that few companies are attempting to do this, possibly because the standards are still not considered disease modifying.

Still, with current treatments costing close to $100,000 a year, anything proposed as a combination therapy could come under pressure. Roche's dominance here will allow it more flexibility, and should lebrikizumab succeed the Swiss group will be the force to be reckoned with here.

But caution is again warranted: tralokinumab and QAX576, IL-13 antibodies from Astrazeneca (AZN) and Novartis (NVS) respectively, have been abandoned in IPF.

Meanwhile, Bristol (BMY) has dibs on Promedior's PRM-151, a recombinant form of human pentraxin-2, in the form of a buyout option for the whole company for $150m initially and up to $1.25bn in future earnouts. Phase II trials completed enrollment at the end of last year, so results in both IPF and myelofibrosis should be in house, though no news has emerged.

Ones to watch in the IPF space
Project Mechanism Company Data due* Enrolment Trial ID
Phase II completed
GLPG1690 Autotaxin inhibitor Galapagos Reported 23 NCT02738801
Pamrevlumab Anti-CTGF MAb Fibrogen Reported 160 NCT01890265
TD139 Galectin-3 inhibitor Galecto Biotech Reported 60 NCT02257177
PBI-4050 Anti-inflammatory & anti-fibrotic Prometic Life Sciences Reported 41 NCT02538536
BG00011 Anti-alpha 5 beta 6 integrin MAb Biogen (via Stromedix buyout) ? 43 NCT01371305
Phase II ongoing
PRM-151 (pentraxin-2) MREG differentiation inducer Promedior (Bristol-Myers option) Mar 2017 117 NCT02550873
SAR156597 Anti-IL-4 & IL-13 bispecific MAb Sanofi Aug 2017 300 NCT02345070 (Estair)
Lebrikizumab Anti-IL-13 MAb Roche Nov 2017 507 NCT01872689
KD025 ROCK 2 inhibitor Kadmon Q4 2017* 36 NCT02688647
GBT440 HbS polymerisation inhibitor Global Blood Therapeutics Q4 2017* 30; 16 NCT02846324; NCT02989168 (Zephyr)
MN-001 Leukotriene, PDE 3 & 4 & 5-LO inhibitor Medicinova Dec 2017 15 NCT02503657
CC-90001 JNK 1 inhibitor Celgene May 2020 135 NCT03142191^
Phase I
GSK3008348 Alpha 5 beta 6 integrin inhibitor Glaxosmithkline Jan 2019 17 NCT03069989
Moving into the clinic?
Autotaxin inhibitor program Autotaxin inhibitor Pharmakea (Celgene option) First clinical trials targeted to start in 2017**
Notes: *according to; **based on company guidance; ^not yet recruiting, according to

This is not Bristol's only involvement in IPF - and fibrotic disease more widely - though its efforts so far have come to naught. An asset licensed from Amira, an LPA 1 receptor antagonist, failed to progress beyond early trials, while an option to buy Galecto on the basis of phase Ib results from its galectin-3 inhibitor TD139 has presumably lapsed.

Small comfort for Bristol could come from royalties on Fibrogen's pamrevlumab, which a very long time ago was created with antibody technology from Medarex, which is now owned by Bristol.

Notably, the Amira asset targeted the same pathway as the autotaxin approach that Galapagos highlighted last week with GLPG1690 with data in only 23 patients. Inhibition of ATX leads to a reduction in lysophosphatidic acid production, which blocks signalling cascades that ultimately drive the development of fibrosis.

Not the big story?

Also gearing up to release results, in the fourth quarter from three trials, is Global Blood Therapeutics (GBT); hopes are high for GBT440's ability to enhance oxygen saturation, which would prompt a decision to move into phase IIb. IPF is not considered a big part of the GBT story, much like Galapagos, so strong results could generate an equally positive share price reaction.

Meanwhile, Prometic (PFSCF) is pushing into phase II/III on the back of data from an open-label, 40-patient phase II trial of PBI-4050 earlier this year - patients treated with the asset appeared to demonstrate a stabilization of disease progression. Two placebo-controlled phase II/III trials, testing the agent as a monotherapy and in combination with Ofev, have been approved by the FDA.

And Celgene (CELG) has a collaboration with Pharmakea that at the end of 2016 was looking to put an autotaxin inhibitor into the clinic this year. Later in 2017 Celgene also plans to start a phase IIa trial with CC-90001, an internally originated compound.

Celgene might be behind the leaders, but it neither it nor any of the other big hitters like Roche and Bristol should be underestimated.

Editor's Note: This article discusses one or more securities that do not trade on a major U.S. exchange. Please be aware of the risks associated with these stocks.

This article was written by

EP Vantage profile picture
EP Vantage is a forward-looking comment and analysis service tailored to the needs of pharma and finance professionals, focusing on the events that will define the future of companies, products and therapy areas. Written by experienced journalists, EP Vantage provides timely financial analysis of regulatory and patent decisions, marketing approvals, licensing deals, and M&A, giving fresh angles and insight to both current and future industry triggers. EP Vantage is powered by EvaluatePharma, the industry leader in consensus forecasts.

Recommended For You

Comments (2)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.